Denali Therapeutics Inc.

NasdaqGS:DNLI 주식 리포트

시가총액: US$3.3b

Denali Therapeutics 경영진

경영진 기준 점검 4/4

Denali Therapeutics CEO는 Ryan Watts, Aug2015 에 임명되었습니다 의 임기는 10.83 년입니다. 총 연간 보상은 $4.75M, 15.1% 급여 및 84.9% 보너스(회사 주식 및 옵션 포함)로 구성됩니다. 는 $46.67M 가치에 해당하는 회사 주식의 1.43% 직접 소유합니다. 경영진과 이사회의 평균 재임 기간은 7.4 년과 7.2 년입니다.

핵심 정보

Ryan Watts

최고경영자

US$4.8m

총 보수

CEO 급여 비율15.11%
CEO 재임 기간10.8yrs
CEO 지분 보유율1.4%
경영진 평균 재임 기간7.4yrs
이사회 평균 재임 기간7.2yrs

최근 경영진 업데이트

Recent updates

Seeking Alpha • May 27

Denali Therapeutics: 'Strong Buy' On AVLAYAH Approval And End Of 2026 FTD-GRN Data

Summary Denali Therapeutics maintains a "Strong Buy" rating following an FDA Accelerated Approval of AVLAYAH for Hunter syndrome and robust pipeline momentum. The company's DNL593 for FTD-GRN is differentiated by restoring both extracellular and lysosomal PGRN; phase 1/2 data readout is expected by the end of 2026. AVLAYAH’s full approval depends on confirmatory COMPASS study results; commercial performance remains unproven post-April 2026 launch. The company holds $1.05B in cash but may need additional funding within 12 months, with a $400M ATM facility available for potential dilution. Read the full article on Seeking Alpha
분석 기사 • May 08

We're Not Very Worried About Denali Therapeutics' (NASDAQ:DNLI) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Seeking Alpha • Mar 20

Denali Therapeutics: Vast Pipeline, First Approval Up Ahead

Summary Denali Therapeutics' stock has significantly dropped from $100 to $15 since 2021, but the company is now heavily derisked with promising product candidates nearing key milestones. Lead asset DNL310 shows strong biomarker data for Hunter syndrome, with plans for a BLA submission and accelerated approval by Q2 2025. The Biogen partnership for Parkinson’s Disease asset DNL151 includes substantial milestone payments and profit-sharing, highlighting its potential impact. Despite past failures, Denali's extensive pipeline and solid financial runway make it a compelling buy at current low stock prices. Read the full article on Seeking Alpha
Seeking Alpha • Jan 09

Denali: Despite ALS Primary Endpoint Failure, Possible Path Forward Remains

Summary Denali Therapeutics Inc.'s DNL343 failed to meet the primary endpoint in the phase 2/3 HEALY ALS trial, but potential biomarker analyses in 2025 may offer a path forward. Despite the trial setback in ALS, Denali's stock remains stable due to continued pre-specified analyses expected in late 2025. BLA filing of tividenofusp alfa for the treatment of patients with MPS II remains on track under the Accelerated Approval Pathway Program in early 2025. Financially, Denali has $1.28 billion in cash but may need additional funding in 2025, posing a risk of shareholder dilution. Read the full article on Seeking Alpha
분석 기사 • Dec 09

We're Hopeful That Denali Therapeutics (NASDAQ:DNLI) Will Use Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Seeking Alpha • Aug 20

Denali Therapeutics: A Promising Biotech With Revolutionary BBB-Crossing Technology

Summary Denali Therapeutics' proprietary Transport Vehicle technology enables drug delivery across the blood-brain barrier, targeting neurodegenerative diseases. DNL310, targeting MPS II, and DNL343 for ALS are key drug candidates with potential, though competition is significant. The company’s $500 million capital raise supports its aggressive R&D investment, providing a runway for developing its pipeline. Despite its promising platform, DNLI still has a relatively high cash burn and regulatory hurdles before achieving drug approval. Due to Denali's high-risk, long-term biotech development, I deem DNLI a DCA "buy" for investors who understand the inherent risks. Read the full article on Seeking Alpha
분석 기사 • Jul 26

Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
분석 기사 • May 23

Revenues Not Telling The Story For Denali Therapeutics Inc. (NASDAQ:DNLI) After Shares Rise 25%

Denali Therapeutics Inc. ( NASDAQ:DNLI ) shareholders would be excited to see that the share price has had a great...
Seeking Alpha • May 13

Denali Therapeutics: MPS Treatment Program Continues With End Of 2024 Data

Summary Denali Therapeutics Inc.'s DNL-310 is currently being explored in an ongoing phase 2/3 COMPASS study for treatment of patients with MPS II; Enrollment completion expected in 2024. Denali is in talks with CDER division of FDA to seek for Accelerated Approval pathway for DNL-310 for the treatment of patients with MPS II. Biomarker and safety data from a phase 1/2 study, using DNL-126 for the treatment of patients with MPS IIIA, expected end of 2024. Another promising program from the pipeline is the development of DNL-343, which is being advanced in the phase 2/3 HEALEY ALS Platform trial for treatment of patients with amyotrophic lateral sclerosis. Read the full article on Seeking Alpha
분석 기사 • Apr 17

An Intrinsic Calculation For Denali Therapeutics Inc. (NASDAQ:DNLI) Suggests It's 44% Undervalued

Key Insights Using the 2 Stage Free Cash Flow to Equity, Denali Therapeutics fair value estimate is US$30.71 Denali...
분석 기사 • Mar 21

Denali Therapeutics Inc.'s (NASDAQ:DNLI) Price Is Right But Growth Is Lacking After Shares Rocket 25%

Those holding Denali Therapeutics Inc. ( NASDAQ:DNLI ) shares would be relieved that the share price has rebounded 25...
Seeking Alpha • Mar 07

Denali: Leveraging Transport Vehicle Technology For Neurological Gains

Summary Denali's stock performance has been flat despite the biotech sector's 20% rise; recently raised $500 million in a PIPE. ALS trial failure with partner Sanofi pressured stock; Denali's focus is on transport vehicle (TV) technology and BBB crossing. Denali boasts a strong financial position with $1.53 billion in cash, extending operational runway significantly. Recommends "buy" based on Denali's innovative TV technology, financial health, and potential in neurological disorders despite biotech risks. Read the full article on Seeking Alpha
분석 기사 • Feb 21

Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
분석 기사 • Jan 26

Improved Revenues Required Before Denali Therapeutics Inc. (NASDAQ:DNLI) Shares Find Their Feet

Denali Therapeutics Inc.'s ( NASDAQ:DNLI ) price-to-sales (or "P/S") ratio of 7x might make it look like a buy right...
분석 기사 • Nov 20

We're Not Very Worried About Denali Therapeutics' (NASDAQ:DNLI) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
분석 기사 • Oct 09

Investor Optimism Abounds Denali Therapeutics Inc. (NASDAQ:DNLI) But Growth Is Lacking

With a median price-to-sales (or "P/S") ratio of close to 10.4x in the Biotechs industry in the United States, you...
분석 기사 • Aug 22

Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

CEO 보수 분석

Ryan Watts의 보수는 Denali Therapeutics의 수익에 비해 어떻게 변했나요?
날짜총 보수급여회사 수익
Mar 31 2026n/an/a

-US$508m

Dec 31 2025US$5mUS$718k

-US$513m

Sep 30 2025n/an/a

-US$499m

Jun 30 2025n/an/a

-US$479m

Mar 31 2025n/an/a

-US$454m

Dec 31 2024US$7mUS$690k

-US$423m

Sep 30 2024n/an/a

-US$427m

Jun 30 2024n/an/a

-US$420m

Mar 31 2024n/an/a

-US$137m

Dec 31 2023US$8mUS$670k

-US$145m

Sep 30 2023n/an/a

-US$124m

Jun 30 2023n/an/a

-US$128m

Mar 31 2023n/an/a

-US$371m

Dec 31 2022US$9mUS$645k

-US$326m

Sep 30 2022n/an/a

-US$303m

Jun 30 2022n/an/a

-US$284m

Mar 31 2022n/an/a

-US$286m

Dec 31 2021US$13mUS$610k

-US$291m

Sep 30 2021n/an/a

US$30m

Jun 30 2021n/an/a

US$56m

Mar 31 2021n/an/a

US$58m

Dec 31 2020US$9mUS$589k

US$71m

Sep 30 2020n/an/a

-US$228m

Jun 30 2020n/an/a

-US$216m

Mar 31 2020n/an/a

-US$215m

Dec 31 2019US$5mUS$567k

-US$198m

보상 대 시장: Ryan의 총 보수(USD4.75M)는 US 시장에서 비슷한 규모 기업의 평균(USD7.00M)보다 낮습니다.

보상과 수익: Ryan의 보상은 지난 1년 동안 회사 실적과 일치했습니다.

CEO

Ryan Watts (50 yo)

10.8yrs
재임 기간
US$4,751,515
보수

Dr. Ryan J. Watts, Ph D., serves as Director at PEEL Therapeutics, Inc. since February 2023. He is the Co-Founder of Denali Therapeutics Inc. and has been its President and Chief Executive Officer since Au...

리더십 팀

이름직위재임 기간보수지분
Ryan Watts
Co-Founder10.8yrsUS$4.75m1.43%
$ 46.7m
Alexander Schuth
Co-Founder11.3yrsUS$4.26m0.42%
$ 13.7m
Dana Andersen
Chief Technical and Manufacturing Officer7.8yrs데이터 없음데이터 없음
Joe Lewcock
Chief Scientific Officer5.9yrs데이터 없음데이터 없음
Chris Walsh
General Counsel7.4yrs데이터 없음데이터 없음
Cindy Dunkle
Chief People Officerno data데이터 없음데이터 없음
Katie Peng
Chief Commercial Officer4.8yrs데이터 없음데이터 없음
Peter Chin
Acting Chief Medical Officer & Head of Developmentless than a year데이터 없음0.13%
$ 4.2m
7.4yrs
평균 재임 기간
54yo
평균 나이

경험이 풍부한 관리: DNLI의 경영진은 노련하고 경험이 풍부합니다(평균 재임 7.4 년).

이사회 구성원

이름직위재임 기간보수지분
Ryan Watts
Co-Founder11.3yrsUS$4.75m1.43%
$ 46.7m
Jay Flatley
Independent Director11.2yrsUS$316.38k0.22%
$ 7.3m
Julian Baker
Independent Chairperson1yrUS$474.35k0.21%
$ 6.8m
Eric Reiman
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
David Schenkein
Independent Director11.2yrsUS$311.38k0.046%
$ 1.5m
David Holtzman
Member of Scientific Advisory Board5.6yrs데이터 없음데이터 없음
Peter Klein
Independent Director8.3yrsUS$318.88k0.017%
$ 567.5k
Jennifer Cook
Independent Director7.6yrsUS$301.38k0.016%
$ 537.4k
Steve Krognes
Independent Director4.1yrsUS$297.15k0.51%
$ 16.8m
Stacie Weninger
Member of Scientific Advisory Board5.4yrs데이터 없음데이터 없음
Henrik Zetterberg
Member of Scientific Advisory Board7.2yrs데이터 없음데이터 없음
Nancy Thornberry
Independent Director5.4yrsUS$306.38k0.016%
$ 509.3k
7.2yrs
평균 재임 기간
62yo
평균 나이

경험이 풍부한 이사회: DNLI의 이사회는 경험이 있음으로 간주됩니다(평균 재임 7.2 년).

기업 분석 및 재무 데이터 상태

데이터최종 업데이트 (UTC 시간)
기업 분석2026/06/11 10:16
종가2026/06/11 00:00
수익2026/03/31
연간 수익2025/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지데이터기간미국 소스 예시 *
기업 재무제표10년
  • 손익계산서
  • 현금흐름표
  • 대차대조표
분석가 컨센서스 추정치+3년
  • 재무 예측
  • 분석가 목표주가
시장 가격30년
  • 주가
  • 배당, 분할 및 기타 조치
지분 구조10년
  • 주요 주주
  • 내부자 거래
경영진10년
  • 리더십 팀
  • 이사회
주요 개발10년
  • 회사 공시

* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Denali Therapeutics Inc.는 31명의 분석가가 다루고 있습니다. 이 중 19명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가기관
null nullBaird
Joel BeattyBaird
Charles MooreBaird